AIDS 2026: Co-Chairs' Choice

Chairs

Draurio Barreira

Ministry of Health

Beatriz Grinsztejn

Fiocruz/INI

Claudia Cortes

Universidad de Chile

Speakers

Draurio Barreira

Ministry of Health

Beatriz Grinsztejn

Fiocruz/INI

Claudia Cortes

Universidad de Chile

Introduction
Eugene Ruzagira

Eugene Ruzagira

MRC/UVRI and LSHTM Uganda Research Unit

Uptake, persistence and preference for long-acting injectable versus oral PrEP among Mobile Men in Uganda and South Africa: primary user effectiveness and implementation outcomes in the Mobile Men trial

Elise Lankiewicz

amfAR

Measuring PEPFAR disruptions at scale: Results from a 46-country implementing partner survey
Sharana Mahomed

Sharana Mahomed

CAPRISA

Safety and preliminary efficacy of 6-monthly subcutaneous CAP256V2LS plus VRC07-523LS for HIV prevention in African women: results of the CAPRISA 012C phase 2 randomised controlled trial

Mutsa Bwakura Dangarembizi

University of Zimbabwe Clinical Research Centre

Every-8-weeks injectable cabotegravir and rilpivirine is superior to daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir in adolescents living with HIV in sub-Saharan Africa: LATA 96-week results
Amy Colson

Amy Colson

Community Resource Initiative

Once-weekly oral islatravir/lenacapavir (ISL/LEN) versus daily standard-of-care therapy in virologically suppressed adults with HIV-1: week 48 results of the ISLEND-2 phase 3 trial

Draurio Barreira

Ministry of Health

Beatriz Grinsztejn

Fiocruz/INI

Claudia Cortes

Universidad de Chile

Mutsa Bwakura Dangarembizi

University of Zimbabwe Clinical Research Centre

Amy Colson

Amy Colson

Community Resource Initiative

Elise Lankiewicz

amfAR

Sharana Mahomed

Sharana Mahomed

CAPRISA

Eugene Ruzagira

Eugene Ruzagira

MRC/UVRI and LSHTM Uganda Research Unit

Q&A and conclusion

Beatriz Grinsztejn

Fiocruz/INI

Jean William Pape

Jean William Pape

Les Centres GHESKIO

IAS President’s Award